EXEL · Exelixis, Inc.

Track EXEL — free

$53.68 -0.71 (-1.31%)

Market Cap

$13.48B

247.78M

Up next

Next earnings call

Nov 8, 2026 Est · unconfirmed · in 11 wks

FQ3-27 quarter ends

~Oct 1, 2026 Est

Latest filing: 10-Q

filed Aug 5, 2026

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Moderate

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +16%

above

Price vs 50-day avg +0%

above

RSI (14) 53

neutral

MACD trend Negative

52-week position 88%

near high

Momentum

relative strength

Very Strong

1-month return −1%

trailing

6-month return +23%

trailing

YTD return +24%

this year

Relative strength +11%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $54 › 200d $47 — 50d above 200d

Institutional flow Accumulating

+7% holders QoQ · +131 funds added

Insider flow Distributing

Net -$2.2M over 90 days · 100% sells

Short interest Falling

11.60% of float · ▼ -7.0% MoM · 13.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

754 holders — near 3-yr high, broad support

Squeeze score 75

high risk · 0–100

Fundamentals

Excellent

Revenue growth +136%

Y/Y

EPS growth +58%

Y/Y

Free cash flow $875.8M

Valuation P/E 17.1

below peers

Buyback $597.8M

remaining

Balance sheet $293.4M

net cash

Quant / Vol

risk profile

Moderate

Volatility 37%

annualized · 1-yr

Max drawdown −16%

past year

ATR 3.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 2 of last 2

Latest guidance · from the 8-K filed Aug 5, 2026

Cost of goods sold, % of net product revenues · fiscal year 2026 Maintained 3.5% – 4.5%

Jan 12, 2026 3.5% – 4.5% Aug 5, 2026 3.5% – 4.5%

Effective tax rate · fiscal year 2026 Maintained 21% – 23%

Jan 12, 2026 21% – 23% Aug 5, 2026 21% – 23%

Prior guidance period ended · from the 8-K filed Nov 4, 2025

Total revenues · fiscal year 2025 $2.3B – $2.35B

Net product revenues · fiscal year 2025 $2.1B – $2.15B

Effective tax rate · fiscal year 2025 17% – 18%

Guided vs delivered · last 2 settled

Total revenues fiscal year 2025

guided $2.3B – $2.35B

guided $2.3B – $2.35B $2.32B In line

Total revenue full year 2024

guided $2.15B – $2.2B

guided $2.15B – $2.2B $2.17B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+16% Bullish

Price vs 50-day avg

+0% Bullish

RSI (14)

53 Neutral

MACD trend

Negative Bearish

52-week position

88% Bullish

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $54 › 200d $47 — 50d above 200d

Institutional flow Accumulating

+7% holders QoQ · +131 funds added

Insider flow Distributing

Net -$2.2M over 90 days · 100% sells

Short interest Falling

11.60% of float · ▼ -7.0% MoM · 13.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

754 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $35 Now $54 · 88% Range high $57

vs 200-day avg +16% vs 50-day avg +0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
CABOMETYX Net Product Revenues	570.6M	second quarter of 2026	—

Cabozantinib Franchise Net Product Revenues	573M	second quarter of 2026	—

COMETRIQ Net Product Revenues	2.4M	second quarter of 2026	—

Non-GAAP Diluted EPS non-GAAP	$0.91	second quarter of 2026	—

Non-GAAP Net Income non-GAAP	237.1M	second quarter of 2026	—

GAAP → non-GAAP reconciliation GAAP GAAP net income 212.05M +12.34M Stock-based compensation - research and development +20.22M Stock-based compensation - selling, general and administrative -7.51M Income tax effect of the above adjustments = Non-GAAP net income 237.1M
Stock Repurchase Program	$750M	May 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
EXEL Exelixis, Inc. this stock	$13.48B	+24.1%	+136.3%	17.1	11.6%
ONC BeOne Medicines Ltd.	$557.05B	+24.0%	+22179.2%	856.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.88B	+21.8%	+46.2%	30.8	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.39B	+8.9%	+20.8%	20.8	3.3%
MRNA Moderna, Inc.	$69.62B	+491.3%	+4.3%	—	12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

754

% held: 105.1%
Net QoQ: -314.9K sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

647

View

Short & Settlement

Short Interest Falling

Shares short

28.7M

Days to cover: 13.4d
Change: -2.2M sh

View

Short Volume

Short vol %

53%

As of: Aug 19, 2026

Short Total

View

Fails to Deliver

FTD shares

619

Value: $34.6K
As of: Jul 31, 2026

View

Off-Exchange

Off-exchange %

37.6%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$2.2M

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Congressional Trades Sell

Member

Donna Shalala

Amount: $1.0K–$15.0K
Traded: Jun 4, 2019

View

Financials

Revenue (FY)

$2.3B

Net income (FY): $782.6M
EPS diluted: $2.78

View

Buybacks

Authorized

$750.0M

Remaining: $597.8M

Spent Remaining

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 5, 2026
This year: 12

View

Proposed Sales

Value

$526.5K

Shares: 9.8K
Filed: Aug 10, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 5, 2026

View

Performance

	5D	20D	120D	MTD	YTD
EXEL	+8.0%	-1.1%	+22.8%	+2.6%	+24.1%
SPY	-0.4%	+2.9%	+11.6%	+3.0%	+12.8%
vs SPY	+8.4%	-4.0%	+11.3%	-0.4%	+11.3%

Capital returns

Buyback program · as of Jul 3, 2026

Authorized

$750.00M

Spent (derived)

$152.20M

Remaining

$597.80M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 939767 CUSIP 30161Q104 13F (30d) 703 filings 653 filers Visit website Investor relations

EXEL · Exelixis, Inc.

Price & Indicators

Up next

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns